Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.47 -1.85 (-3.34%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗

November 21, 2021

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Via The Motley Fool

Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗

November 20, 2021

The companies are collaborating on a potential blockbuster.

Via The Motley Fool

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Why CRISPR Therapeutics Stock Fell 18.4% in October ↗

November 04, 2021

The gene-editing specialist's stock is now down roughly 37% year to date.

Via The Motley Fool

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗

November 04, 2021

Vertex plans to develop gene-editing therapies with Mammoth Biosciences.

Via The Motley Fool

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

October 20, 2021

The company's value isn't reflected in typical performance metrics.

Via The Motley Fool

2 Gene-Editing Stocks to Have on Your Radar Right Now ↗

October 17, 2021

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Via The Motley Fool

2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗

October 16, 2021

These two novel-drug makers could be top takeover targets next year.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today ↗

October 16, 2021

The returns haven't been half bad, to say the least.

Via The Motley Fool

Crispr: A Fallen Angel In Gene Editing ↗

October 16, 2021

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...

Via Talk Markets

Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗

October 15, 2021

It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields.

Via Investor's Business Daily

BZ Chart Of The Day: Is Crisper Therapeutics About To Rally? ↗

October 15, 2021

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form...

Via Benzinga

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗

October 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...

Via Benzinga

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today ↗

October 13, 2021

Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial.

Via InvestorPlace

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

October 13, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...

Via Benzinga

Why CRISPR Therapeutics Stock Is Sinking Today ↗

October 13, 2021

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Tumbling Today ↗

October 13, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

20 Stocks Moving in Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-...

Via Benzinga

Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall? ↗

October 12, 2021

Crispr is planning to begin a registrational test in the first quarter of 2022.

Via Investor's Business Daily

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...

Via Benzinga

Why CRISPR Therapeutics Stock Fell 10.4% Last Month ↗

October 07, 2021

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

Via The Motley Fool

These 3 Top Healthcare Stocks Are Screaming Buys Right Now ↗

September 29, 2021

If the market crashes these companies could be insulated.

Via The Motley Fool

Biotech Playbook Revisited As Technicals Weaken ↗

September 27, 2021

Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...

Via Talk Markets

3 Explosive Biotech Stocks That Could 10X in 10 Years ↗

September 16, 2021

They're leaders in therapeutic areas with massive growth potential.

Via The Motley Fool

Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market ↗

September 09, 2021

Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.

Via Talk Markets

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.